Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 251

3.

Fighting graft--it's academic. Medical centers must embrace conflict rules: critics.

Romano M.

Mod Healthc. 2006 Jan 30;36(5):8-10. No abstract available.

PMID:
16479773
4.

AMA forges ahead. Unveiling of educational campaign paid by drug industry triggers new criticism.

Romano M.

Mod Healthc. 2001 Sep 10;31(37):22-3. No abstract available.

PMID:
11573355
5.

The relationship between paediatricians and commerce.

Hilliard T, Chambers T.

Paediatr Respir Rev. 2006 Mar;7(1):54-9. Epub 2005 Dec 6. Review.

PMID:
16473818
6.

Is continuing medical education a drug-promotion tool?: YES.

Steinman MA, Baron RB.

Can Fam Physician. 2007 Oct;53(10):1650-7. English, French. No abstract available.

7.

Conflicts of interest between physicians and the pharmaceutical industry and special interest groups.

Schetky DH.

Child Adolesc Psychiatr Clin N Am. 2008 Jan;17(1):113-25, ix-x. Review.

PMID:
18036482
8.

The agenda for continuing medical education--limiting industry's influence.

Morris L, Taitsman JK.

N Engl J Med. 2009 Dec 17;361(25):2478-82. doi: 10.1056/NEJMsb0905411. No abstract available.

PMID:
20018969
9.

[Drug indoctrination or education? You are member of the county council's political committee].

Andrén-Sandberg A.

Lakartidningen. 2003 Oct 16;100(42):3328-32. Swedish. No abstract available.

PMID:
14619046
10.

Adapting to decreased industry support of CME: lifelong education in an "industry-lite" world.

Yager J, Silverman JJ, Rapaport MH.

Acad Psychiatry. 2011 Mar-Apr;35(2):101-5. doi: 10.1176/appi.ap.35.2.101. No abstract available.

PMID:
21403160
11.

Industry support of continuing medical education: evidence and arguments.

Goold SD, Campbell EG.

Hastings Cent Rep. 2008 Nov-Dec;38(6):34-7. No abstract available.

PMID:
19192715
12.

Future directions in industry funding of continuing medical education.

Steinbrook R.

Arch Intern Med. 2011 Feb 14;171(3):257-8. doi: 10.1001/archinternmed.2010.498. No abstract available.

PMID:
21325116
13.

Drug makers battle a U.S. plan to curb rewards for doctors.

Pear R.

N Y Times Web. 2002 Dec 26:A1, A28. No abstract available.

PMID:
12561833
14.

Don't restrict funding from drug companies for doctors' education.

Skolnik N.

BMJ. 2013 Nov 8;347:f6452. doi: 10.1136/bmj.f6452. No abstract available.

PMID:
24212106
15.

Successes, challenges emerge from efforts to shift away from industry-funded CME.

Kuehn BM.

JAMA. 2010 Aug 18;304(7):729-31. doi: 10.1001/jama.2010.1062. No abstract available. Erratum in: JAMA. 2010 Oct 13;304(14):1557.

PMID:
20716730
16.
17.

Proposed guidelines for housestaff interaction with pharmaceutical companies.

Forrest DM, Ruedy J.

Ann R Coll Physicians Surg Can. 1993 Oct;26(5):291-3.

PMID:
15362243
18.

Doctors' interactions with the pharmaceutical industry: science or commerce?

Komesaroff P.

Intern Med J. 2001 Nov;31(8):446-7. No abstract available.

PMID:
11720056
19.

Financial support of continuing medical education.

Steinbrook R.

JAMA. 2008 Mar 5;299(9):1060-2. doi: 10.1001/jama.299.9.1060. No abstract available.

PMID:
18319417
20.

Continuing medical education--limiting industry's influence.

Colburn L, Dorman T.

N Engl J Med. 2010 Mar 18;362(11):1052; author reply 1053-4. doi: 10.1056/NEJMc1000545. No abstract available.

Supplemental Content

Support Center